This company has been marked as potentially delisted and may not be actively trading. Seneca Biopharma (SNCA) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock SNCA vs. OTLK, IPSC, QNCX, ZIVO, OKYO, BLUE, TNYA, ATRA, COEP, and DYAIShould you be buying Seneca Biopharma stock or one of its competitors? The main competitors of Seneca Biopharma include Outlook Therapeutics (OTLK), Century Therapeutics (IPSC), Quince Therapeutics (QNCX), ZIVO Bioscience (ZIVO), OKYO Pharma (OKYO), bluebird bio (BLUE), Tenaya Therapeutics (TNYA), Atara Biotherapeutics (ATRA), Coeptis Therapeutics (COEP), and Dyadic International (DYAI). These companies are all part of the "medical" sector. Seneca Biopharma vs. Outlook Therapeutics Century Therapeutics Quince Therapeutics ZIVO Bioscience OKYO Pharma bluebird bio Tenaya Therapeutics Atara Biotherapeutics Coeptis Therapeutics Dyadic International Seneca Biopharma (NASDAQ:SNCA) and Outlook Therapeutics (NASDAQ:OTLK) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, community ranking, earnings, dividends, profitability, analyst recommendations, valuation and risk. Which has better earnings & valuation, SNCA or OTLK? Seneca Biopharma has higher revenue and earnings than Outlook Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSeneca Biopharma$10K1,370.54-$8.35MN/AN/AOutlook TherapeuticsN/AN/A-$75.37M-$7.42-0.21 Does the media favor SNCA or OTLK? In the previous week, Seneca Biopharma's average media sentiment score of 0.00 equaled Outlook Therapeutics'average media sentiment score. Company Overall Sentiment Seneca Biopharma Neutral Outlook Therapeutics Neutral Which has more volatility and risk, SNCA or OTLK? Seneca Biopharma has a beta of 1.83, suggesting that its stock price is 83% more volatile than the S&P 500. Comparatively, Outlook Therapeutics has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500. Is SNCA or OTLK more profitable? Outlook Therapeutics has a net margin of 0.00% compared to Seneca Biopharma's net margin of -230.34%. Outlook Therapeutics' return on equity of 0.00% beat Seneca Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Seneca Biopharma-230.34% -122.20% -110.61% Outlook Therapeutics N/A N/A -225.12% Does the MarketBeat Community prefer SNCA or OTLK? Outlook Therapeutics received 151 more outperform votes than Seneca Biopharma when rated by MarketBeat users. Likewise, 71.12% of users gave Outlook Therapeutics an outperform vote while only 63.64% of users gave Seneca Biopharma an outperform vote. CompanyUnderperformOutperformSeneca BiopharmaOutperform Votes1463.64% Underperform Votes836.36% Outlook TherapeuticsOutperform Votes16571.12% Underperform Votes6728.88% Do insiders & institutionals believe in SNCA or OTLK? 5.2% of Seneca Biopharma shares are owned by institutional investors. Comparatively, 11.2% of Outlook Therapeutics shares are owned by institutional investors. 2.1% of Seneca Biopharma shares are owned by company insiders. Comparatively, 4.8% of Outlook Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts recommend SNCA or OTLK? Outlook Therapeutics has a consensus price target of $10.20, suggesting a potential upside of 558.06%. Given Outlook Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Outlook Therapeutics is more favorable than Seneca Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Seneca Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Outlook Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 SummaryOutlook Therapeutics beats Seneca Biopharma on 9 of the 13 factors compared between the two stocks. Get Seneca Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for SNCA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNCA vs. The Competition Export to ExcelMetricSeneca BiopharmaBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.71M$2.98B$5.57B$8.05BDividend YieldN/A1.87%5.36%4.23%P/E RatioN/A30.5222.8119.02Price / Sales1,370.54497.19406.32107.04Price / CashN/A168.6838.1834.62Price / Book0.603.236.794.34Net Income-$8.35M-$71.70M$3.23B$248.27M Seneca Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNCASeneca BiopharmaN/A$0.79+1.5%N/A-89.8%$13.71M$10,000.000.007Gap UpOTLKOutlook Therapeutics1.092 of 5 stars$1.50+2.0%$10.20+580.0%-82.0%$48.03MN/A-0.2020Gap UpIPSCCentury Therapeutics1.8622 of 5 stars$0.54flat$4.40+714.8%-81.8%$46.46M$6.59M-0.29170Upcoming EarningsHigh Trading VolumeQNCXQuince Therapeutics2.0758 of 5 stars$1.05flat$8.00+661.9%+7.6%$46.29MN/A-0.8560Upcoming EarningsZIVOZIVO BioscienceN/A$12.00flatN/A+74.6%$45.49M$15,850.00-2.4610Upcoming EarningsOKYOOKYO Pharma2.7524 of 5 stars$1.34+14.5%$7.00+422.4%-10.4%$45.34MN/A0.007Short Interest ↓Gap UpBLUEbluebird bio2.1588 of 5 stars$4.34+11.3%$44.60+927.6%-78.1%$42.49M$83.81M-0.12520Upcoming EarningsTNYATenaya Therapeutics3.6433 of 5 stars$0.45-0.7%$6.25+1,274.2%-88.9%$39.83MN/A-0.32110Short Interest ↓Gap DownATRAAtara Biotherapeutics3.5807 of 5 stars$6.74+9.8%$17.75+163.4%-53.3%$39.49M$128.94M-0.26330Upcoming EarningsGap UpCOEPCoeptis Therapeutics0.6664 of 5 stars$11.60+3.7%N/A+13.2%$39.03MN/A-2.002Gap DownDYAIDyadic International2.8485 of 5 stars$1.21-3.2%$6.00+395.9%-16.1%$36.41M$3.50M-5.267Gap Down Related Companies and Tools Related Companies Outlook Therapeutics Alternatives Century Therapeutics Alternatives Quince Therapeutics Alternatives ZIVO Bioscience Alternatives OKYO Pharma Alternatives bluebird bio Alternatives Tenaya Therapeutics Alternatives Atara Biotherapeutics Alternatives Coeptis Therapeutics Alternatives Dyadic International Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNCA) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seneca Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seneca Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SNCA Stock Free SNCA Stock Alerts